接受术前化疗的乳腺癌患者生活质量评分的预后价值。
Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy.
机构信息
Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan.
出版信息
BJS Open. 2018 Nov 26;3(1):38-47. doi: 10.1002/bjs5.50108. eCollection 2019 Feb.
BACKGROUND
Recently, evaluation of quality of life (QOL) has been recognized as a significant outcome measure in the treatment of several cancers. In this study, the Anti-Cancer Drugs-Breast (ACD-B) QOL score was used to assess disease-specific survival in women with breast cancer undergoing preoperative chemotherapy (POC).
METHODS
QOL-ACD-B scores were evaluated before and after POC. The cut-off value of QOL-ACD-B contributing to events such as relapse or death was calculated by receiver operating characteristic (ROC) curve analysis.
RESULTS
In 300 women with breast cancer treated with POC, QOL was significantly reduced ( < 0·001). A high QOL-ACD-B score before POC was an independent factor in the multivariable analysis of overall survival (hazard ratio 0·26, 95 per cent c.i. 0·04 to 0·96).
CONCLUSION
Evaluation by QOL-ACD-B before POC may be useful to predict the prognosis of patients with breast cancer undergoing POC.
背景
最近，生活质量（QOL）的评估已被认为是治疗多种癌症的重要结果衡量标准。在这项研究中，使用抗癌症药物 - 乳房（ACD-B）QOL 评分来评估接受术前化疗（POC）的乳腺癌女性的疾病特异性生存。
方法
在 POC 前后评估 QOL-ACD-B 评分。通过接收者操作特征（ROC）曲线分析计算 QOL-ACD-B 评分的截止值，该值有助于复发或死亡等事件发生。
结果
在接受 POC 治疗的 300 名乳腺癌女性中，QOL 显著降低（<0·001）。POC 前的高 QOL-ACD-B 评分是多变量分析中总体生存的独立因素（风险比 0·26，95%置信区间 0·04 至 0·96）。
结论
在 POC 之前进行 QOL-ACD-B 评估可能有助于预测接受 POC 的乳腺癌患者的预后。
Zotero 插件